Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT00022633 Terminated - Bladder Cancer Clinical Trials

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

Start date: July 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and paclitaxel in treating patients who have advanced or recurrent cancer of the urinary tract.

NCT ID: NCT00022191 Completed - Bladder Cancer Clinical Trials

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer

Start date: May 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract cancer.

NCT ID: NCT00021099 Completed - Clinical trials for Stage IV Bladder Cancer

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Start date: June 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00021021 Completed - Kidney Cancer Clinical Trials

RPI.4610 in Treating Patients With Metastatic Kidney Cancer

Start date: September 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00020540 Completed - Kidney Cancer Clinical Trials

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Start date: March 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing. Biological therapy may be an effective treatment for metastatic melanoma and metastatic kidney cancer. PURPOSE: Phase I trial to study the effectiveness of flt3L combined with CD40-ligand in treating patients who have metastatic melanoma or metastatic kidney cancer.

NCT ID: NCT00019955 Completed - Kidney Cancer Clinical Trials

Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)

Start date: March 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiofrequency interstitial tissue ablation may kill tumor cells by heating tumors to several degrees above body temperature. PURPOSE: This phase II trial is studying radiofrequency interstitial tissue ablation to see how well it works in treating patients with localized renal cell carcinoma (kidney cancer).

NCT ID: NCT00019630 Completed - Brain Tumor Clinical Trials

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

Start date: July 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have refractory solid tumors.

NCT ID: NCT00018941 Completed - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Start date: April 1991
Phase: Phase 3
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. It is not yet known which regimen of interleukin-2 is most effective for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of interleukin-2 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00017329 Completed - Kidney Cancer Clinical Trials

PS-341 in Treating Patients With Metastatic Kidney Cancer

Start date: April 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic kidney cancer.

NCT ID: NCT00016939 Completed - Kidney Cancer Clinical Trials

Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

Start date: May 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable or metastatic kidney cancer.